NCT06923488View on ClinicalTrials.gov

Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions

Myelodysplastic Syndromes

Interventions

DRUG

Leflunomide 10mg

Leflunomide 10mg tablet

DRUG

Leflunomide 20mg

Leflunomide 20mg tablet

DRUG

Decitabine

Decitabine dose of 20 mg/m2

Trial Locations (1)

26506

RECRUITING

West Virginia University Cancer Institute, Morgantown

All Listed Sponsors

lead

West Virginia University

OTHER

NCT06923488 - Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter